Skip to main content
SpringerLink
Log in

Nierenfunktion bei Herzinsuffizienz

  • Chapter
Kardiovaskuläre Forschung 2000

  • 19 Accesses

Zusammenfassung

In Abhängigkeit von der Schwere des Pumpenversagens besteht bei Patienten mit Herzinsuffizienz auch eine Niereninsuffizienz. Umgekehrt ist die chronische Niereninsuffizienz mit kardialen und kardiovaskulären Komplikationen assoziiert. Die Prognose der Patienten mit chronischer Niereninsuffizienz bei asymptomatischen und symptomatischen Patienten mit linksventrikulärer systolischer Dysfunktion lässt sich aus der SOLVD-Studie ableiten: Patienten mit einer Kreatininclearance < 60 ml/min hatten ein relatives erhöhtes Risiko von

  • 1,41 im Hinblick auf die Gesamtmortalität (p < 0,001)

  • 1,68 im Hinblick auf das Linksherzversagen (< 0,001)

  • 1,33 im Hinblick auf die Hospitalisierung wegen Herzversagen (p < 0,001).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 39.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Avers CR, Davis JO, Lieberman F, Carpenter CCJ, Berman M (1962) The effects of chronic hepatic venous congestion on the metabolism of d,l-aldosterone and d-aldosterone. J Clin Invest 41: 884–895

    Article  Google Scholar 

  2. Azizi C, Maistre G, Kalotka H, Isnard R, Barthelemy C, Masson F, Pham P, Pousset F, Eurin J, Lechat P, Kimajda M, Carayon A (1996) Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 148: 51–57

    Article  PubMed  CAS  Google Scholar 

  3. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD (1995) Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76: 1259–1265

    Article  PubMed  CAS  Google Scholar 

  4. Baudouin SV (1997) Oedema and cor pulmonale revisited. Thorax 52: 401–402

    Article  PubMed  CAS  Google Scholar 

  5. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H (1982) Antihypertensive therapy with MK 421: angiotensin II renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4: 966–972

    Article  PubMed  CAS  Google Scholar 

  6. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B (1993) Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 33: 40–45

    PubMed  CAS  Google Scholar 

  7. Christ M, Kellner M, Wehling M, Lombès M, Ertl G, Fraccarollo D, Bauersachs J (2001) Increased aldosterone synthase and type I mineralocorticoid receptor expression in experimental chronic heart failure (submitted for publication )

    Google Scholar 

  8. CIBIS II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomised trial. Lancet 353: 9–13

    Article  Google Scholar 

  9. Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Murray GD, Gillen G (1984) Captopril in heart failure: a double blind controlled trial. Br Heart J 52: 530–535

    Article  PubMed  CAS  Google Scholar 

  10. Cody R, Haas G, Binkley P, Capers Q, Kelly R (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504–509

    PubMed  CAS  Google Scholar 

  11. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303–310

    Article  PubMed  CAS  Google Scholar 

  12. Currie MG, Geller DM, Cole BR, Siegel NR, Fok KF, Adams SP, Eubanks SR, Galluppi GR, Needleman P (1984) Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science 223: 67–69

    Article  PubMed  CAS  Google Scholar 

  13. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL (1997) Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 36: 246–255

    Article  PubMed  CAS  Google Scholar 

  14. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD (1996) Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 77: 828–831

    Article  PubMed  CAS  Google Scholar 

  15. Davis JO (1965) The physiology of congestive heart failure. In: Hamilton WE (ed) Handbook of Physiology. II. Circulation ( 3 ). American Physiological Society, Washington, pp 2071–2122

    Google Scholar 

  16. De Zeeuw D, Janssen WM, De Jong PE (1992) Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 41: 1115–1133

    Article  PubMed  Google Scholar 

  17. Dietz JR, Nazian SJ, Vesely DL (1991) Release of ANF, proANF 1–98, and proANF 31–67 from isolated rat atria by atrial distension. Am J Physiol 260: H1774 - H1778

    PubMed  CAS  Google Scholar 

  18. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681–689

    Article  PubMed  CAS  Google Scholar 

  19. Druml W (1998) The heart and kidney. Wien Klin Wochenschr 110: 69–71

    PubMed  CAS  Google Scholar 

  20. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN (1998) Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19: 1371–1376

    Article  PubMed  CAS  Google Scholar 

  21. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH (1981) Relation of the renin angiotensinaldosterone system to clinical state in congestive heart failure. Circulation 63: 645–651

    Article  PubMed  CAS  Google Scholar 

  22. Feenstra J, in’t Veld BA, van der Linden PD, Grobbee DE, Stricker BH (1998) Risk factors for mortality in user of ibopamine. Br J Clin Pharmacol 46: 71–77

    CAS  Google Scholar 

  23. Firth JD, Raine AEG, Ledingham JGG (1988) Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 7: 1033–1035

    Article  Google Scholar 

  24. Frangiosa A, Spitali L, Molino D, Cirillo E, De Santo LS, Marra C, Maiello C, De Vivo F, Pascale C, Favazzi P, Di Leo VA, De Santo NG, Anastasio P (1999) Renal reserve is normal in patients with dilative cardiomyopathy waiting for heart transplantation. Miner Electrolyte Metab 25: 24–27

    Article  PubMed  CAS  Google Scholar 

  25. Franz M, Woloszczuk W, Hörl WH (2000) N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 58: 374–383

    Article  PubMed  CAS  Google Scholar 

  26. Franz M, Woloszczuk W, Hörl WH (2001) Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 59: 1928–1934

    Article  PubMed  CAS  Google Scholar 

  27. Franz M, Woloszczuk W, Hörl WH (2001) Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 59: 1928–1934

    Article  PubMed  CAS  Google Scholar 

  28. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S (1993) Cloning and expression of apical membrane water channel of rat kidney collection tubule. Nature 361: 549–552

    Article  PubMed  CAS  Google Scholar 

  29. Habibullah AA, Villarreal D, Freeman RH, Dietz JR, Vesely DL, Simmons JC (1995) Atrial natriuretic peptide fragments in dogs with experimental heart failure. Clin Exp Pharmacol Physiol 22: 130–135

    Article  PubMed  CAS  Google Scholar 

  30. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI (1986) Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73: 615–621

    Article  PubMed  CAS  Google Scholar 

  31. Hauser AC, Hörl WH (2001) AT,-Rezeptoren-Antagonisten aus nephrologischer Sicht. Wien Med Wochenschr 151: 160–164

    PubMed  CAS  Google Scholar 

  32. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, De Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203–210

    PubMed  CAS  Google Scholar 

  33. Hörl WH (1996) ACE-Hemmer and Niere. Wien med Wschr 146: 450–453

    PubMed  Google Scholar 

  34. Kos T, Pacher R, Wimmer A, Bojic A, Hülsmann M, Frey B, Mayer G, Yilmaz N, Skvarilova L, Spinar J, Vitovec J, Toman J, Woloszczuk W, Stanek B (1998) Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Wien Klin Wochenschr 110: 89–95

    PubMed  CAS  Google Scholar 

  35. Laragh JH (1962) Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II: further evidence for renal adrenal interaction from studies in hypertension and cirrhosis. Circulation 25: 1015–1023

    PubMed  CAS  Google Scholar 

  36. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr (1993) Circulating N-terminal atrial natriuretic peptides as a marker for symptomless left ventricular dysfunction. Lancet 341: 1105–1109

    Article  PubMed  CAS  Google Scholar 

  37. Maack T (1996) Role of atrial natriuretic factor in volume control. Kidney Int 49: 1732–1737

    Article  PubMed  CAS  Google Scholar 

  38. MacFadyen RJ, Barr CS, Struthers AD (1997) Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35: 30–34

    Article  PubMed  CAS  Google Scholar 

  39. Madsen BK, Keller N, Christiansen E, Christensen NJ (1995) Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during expercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and excersie capacity. J Card Fail 1: 207–216

    Article  PubMed  CAS  Google Scholar 

  40. Maki M, Takayanagi R, Misono KS, Pandey KN, Tibbetts C, Inagami T (1984) Structure of rat atrial natriuretic factor precursor deduced from cDNA sequence. Nature 309: 722–724

    Article  PubMed  CAS  Google Scholar 

  41. Martin PY (2000) Recent advances in the understanding of water metabolism in heart failure (involvement of aquaporin). Kidney Blood Press Res 23: 193–194

    PubMed  CAS  Google Scholar 

  42. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW (1999) Selective V2 receptor antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 10: 2165–2170

    PubMed  CAS  Google Scholar 

  43. Martin DR, Pevahouse JB, Trigg DJ, Vesely DL, Buerkert JE (1990) Three peptides from the ANF prohormone NH(2) terminus are natriuretic and/or kaliuretic. Am J Physiol 258: F1401–1408

    PubMed  CAS  Google Scholar 

  44. Martin PY, Schrier RW (1998) Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 449: 415–426

    Article  PubMed  Google Scholar 

  45. McMurray JJ, Ray SG, Abdullah I, Dergie HJ, Morton JJ (1992) Plasma endothelin in chronic heart failure. Circulation 85: 1374–1379

    PubMed  CAS  Google Scholar 

  46. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999) Effect of metoprolol CR/XL in chronic heart failure. Lancet 353: 2001–2007

    Article  Google Scholar 

  47. Nakao K, Itoh H, Saito Y, Mukoyama M, Ogawa Y (1996) The natriuretic peptide family. Curr Opin Nephrol Hypertens 5: 4–11

    Article  PubMed  CAS  Google Scholar 

  48. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA (1995) Vasopressin increases water permeability of kidney collection duct by inducing translocation of aquaporinCD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013–1017

    Article  PubMed  CAS  Google Scholar 

  49. Nishikimi T, Kawano Y, Saito Y, Matsuoka H (1996) Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27: 275–282

    Article  PubMed  CAS  Google Scholar 

  50. Ogawa Y, Itoh H, Nakao K (1995) Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 22: 49–53

    Article  PubMed  CAS  Google Scholar 

  51. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, Ogris E, Rödler S, Wutte M, Hartter E (1993) Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 71: 1293–1299

    Article  PubMed  CAS  Google Scholar 

  52. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27: 633–641

    Article  PubMed  CAS  Google Scholar 

  53. Packer M, Cohn JN, Abraham WT, Colucci WS, Fowler MB, Greenberg BH, Leier CV, Massie BM, Young JB (1999) Consensus recommendations for the management of chronic heart failure. Am J Cardiol 83: 1A - 38A

    Article  Google Scholar 

  54. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF (1999) Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 100: 2312–2318

    Google Scholar 

  55. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Fiaker GC et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677

    Article  PubMed  CAS  Google Scholar 

  56. Philbin EF, Santella RN, Rocco TA Jr (1999) Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc 47: 302–208

    PubMed  CAS  Google Scholar 

  57. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717

    Article  PubMed  CAS  Google Scholar 

  58. Pousset F, Issnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18: 254–258

    PubMed  CAS  Google Scholar 

  59. Reardon LC, Macpherson DS (1998) Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158: 26–32

    Article  PubMed  CAS  Google Scholar 

  60. Riegger GA (1993) Lessons from recent randomized controlled trials for the management of congestive heart failure. Am J Cardiol 71: 38–40

    Article  Google Scholar 

  61. Riegger GA (1993) ACE inhibitors in early stages of heart failure. Circulation 87 (suppl 5): IV117–119

    Google Scholar 

  62. Riegger GA, Elsner D, Forssmann WG, Kromer EP (1990) Effects of ANP-(95–126) in dogs before and after induction of heart failure. Am J Physiol 259: H1643–1648

    PubMed  CAS  Google Scholar 

  63. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr (1998) Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension 31: 451–458

    PubMed  CAS  Google Scholar 

  64. Rodeheffer, RJ, Lerman A, Heublein DM, Burnett JC (1992) Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 67: 719–724

    PubMed  CAS  Google Scholar 

  65. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91: 457–465

    Article  PubMed  CAS  Google Scholar 

  66. Stafford RS, Saglam D, Blumenthal D (1997) National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 157: 2460–2464

    Article  PubMed  CAS  Google Scholar 

  67. Stanek B, Frey B, Hülsmann M, Koller-Strametz J, Hartter E, Schuller M, Ogris E, Maurer G, Pacher R (1997) Validation of big endothelin plasma levels compared to established neuro-humoral markers in patients with severe chronic heart failure. Transplant Proc 29: 595–596

    Article  PubMed  CAS  Google Scholar 

  68. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730–1736

    Article  PubMed  CAS  Google Scholar 

  69. Tait JF, Bougas J, Tait SAS, Flood C (1965) Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 25: 219–228

    Article  PubMed  CAS  Google Scholar 

  70. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828

    Google Scholar 

  71. The Consensus Trial Study Group (1987) Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435

    Article  Google Scholar 

  72. The Solvd Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–692

    Article  Google Scholar 

  73. The Solvd Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302

    Article  Google Scholar 

  74. Thibault G, Murthy KK, Gutkowska J, Seidah NG, Lazure C, Chretien M, Cantin M (1988) NH2terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides 9: 47–53

    Article  PubMed  CAS  Google Scholar 

  75. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Kinoshita M (1995) Prognostic value of plasma sluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 76: 803–808

    Article  PubMed  CAS  Google Scholar 

  76. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M (1994) Relation between endothelin1 spillover in the lungs and pulmonary resistance in patients with chronic heart failure. J Am Coll Cardiol 23: 1427–1433

    Article  PubMed  CAS  Google Scholar 

  77. Vesely DL, Bayliss JM, Sallman AL (1987) Human prepro atrial natriuretic factor 26–55, 56–92, and 104–123 increase renal guanylate cyclase activity. Biochem Biophys Res Commun 143: 186–193

    CAS  Google Scholar 

  78. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD (1994) Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90: 1129–1140

    PubMed  CAS  Google Scholar 

  79. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA (1987) Atrial natriuretic prohormone peptides 1–30, 31–67, and 79–98 vasodilate the aorta. Biochem Biophys Res Commun 148: 1540–1548

    CAS  Google Scholar 

  80. Villarreal D, Freeman RH (1995) Til death do us part: a case of failed affection. Cardiovasc Res 30: 27–30

    PubMed  CAS  Google Scholar 

  81. Villarreal D, Freeman RH, Traban A, Reams GP (1999) Modulation of renin secretion by atrial natriuretic factor prohormone fragment 31–67. Am J Sci 318: 330–335

    CAS  Google Scholar 

  82. Wang W (1994) Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 24: 571–575

    PubMed  CAS  Google Scholar 

  83. Warner L, Skorecki K, Blendis LM, Epsetin M (1993) Atrial natriuretic factor and liver disease. Hepatology 17: 500–513

    Article  PubMed  CAS  Google Scholar 

  84. Weber KT (1999) Aldosterone and spironolactone in heart failure. N Engl J Med 341: 753–755

    Article  PubMed  CAS  Google Scholar 

  85. Weber KT, Villarreal D (1993) Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 71 (suppl): 3A - 11A

    Article  PubMed  CAS  Google Scholar 

  86. Weston MW, Cintron GB, Giordano AT, Vesely DL (1994) Normalization of circulating atrial natriuretic peptides in cardiac transplant recipients. Am Heart J 127: 129–142

    Article  PubMed  CAS  Google Scholar 

  87. Winters CJ, Sallman AL, Meadows J, Rico DM, Vesely DL (1988) Two new hormones: prohormone atrial natriuretic peptides 1–30 and 31–67 circulate in man. Biochem Biophys Res Commun 150: 231–236

    Article  PubMed  CAS  Google Scholar 

  88. Winters CJ, Vesely DL (1991) Change in plasma immunoreactive N-terminus, C-terminus, and 4.000-dalton midportion of atrial natriuretic factor prohormone with hemodialysis. Nephron 58: 17–22

    Article  PubMed  CAS  Google Scholar 

  89. Xu DL, Martin PY, Ohara M, St. John J, Pattison T, Meng X, Morris K, Kim KJ, Schrier RW (1997) Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99: 1500–1505

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Nephrologie und Dialyse, Medizinische Universitätsklinik III, Währinger Gürtel 18-20, 1090, Wien, Austria

    Prof. Dr. Dr. W. H. Hörl FRCP

Authors
  1. W. Druml
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Dr. W. H. Hörl FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Universitätsklinik, Josef-Schneider-Str. 2, 97080, Würzburg, Deutschland

    Georg Ertl

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Druml, W., Hörl, W.H. (2001). Nierenfunktion bei Herzinsuffizienz. In: Ertl, G. (eds) Kardiovaskuläre Forschung 2000. Steinkopff. https://doi.org/10.1007/978-3-642-93722-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93722-4_4

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1308-2

  • Online ISBN: 978-3-642-93722-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation